People · Operator
Named in public records as an officer, director or promoter · active 2016–2019 · Biotechnology, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Demetrix, Inc. | — | Biotechnology | Series C | $59.0M | $2.0B | 2017 |
| Lygos, Inc. | — | Biotech | Series B | $41.7M | $432.7M | 2016 |
Jay Keasling at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Keasling on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brad Gillespie | 1 | 10 |
| Marc Riiska | 1 | 4 |
| Jeffrey Dietrich | 1 | 2 |
| Jeffrey A. Dietrich | 1 | 1 |
| Leonard A. Katz | 1 | 1 |
| Jeffrey Ubersax | 1 | 1 |
| Darren Platt | 1 | 1 |
| Cynthia Bryant | 1 | 1 |
| Haorui Zhang | 1 | 1 |
| William Haseltine | 1 | 1 |
| Jeff Ubersax | 1 | 1 |
| Eric Steen | 1 | 1 |
| Eric D. Steen | 1 | 1 |
| Jay D. Keasling | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.